QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cerus-q2-2024-gaap-eps-003-beats-004-estimate-sales-45079m-miss-46627m-estimate

Cerus (NASDAQ:CERS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.04) by 25 p...

 cantor-fitzgerald-maintains-overweight-on-cerus-raises-price-target-to-4

Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:CERS) with a Overweight and raises the price target from $3 to...

 craig-hallum-initiates-coverage-on-cerus-with-buy-rating-announces-price-target-of-5

Craig-Hallum initiates coverage on Cerus (NASDAQ:CERS) with a Buy rating and announces Price Target of $5.

 perion-network-cuts-sales-outlook-joins-range-resources-and-other-big-stocks-moving-lower-in-mondays-pre-market-session

U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.

 cerus-corporation-announces-fda-approval-of-extended-shelf-life-for-intercept-platelet-processing-sets-doubling-previous-shelf-life

Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-mon...

 cathie-woods-ark-invest-sells-another-tranche-of-block-shares-even-as-bitcoin-price-stages-a-recovery

On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CR...

 why-blood-components-focused-cerus-stock-is-rising-tuesday

Cerus reports results from the ReCePI Phase 3 trial for INTERCEPT Red Blood Cells, meeting the primary efficacy endpoint in car...

Core News & Articles
Market-Moving News for March 19th
03/19/2024 12:41:16

CERS: 64% | Cerus Corporation Announces Its ReCePI Phase 3 Trial Of INTERCEPT Blood System Met Its Primary Efficacy Endpoint; S...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION